XAV-19

XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2. The therapy offers three beneficial effects: the ability to neutralize the virus, reduce inflammatory responses, and the absence of aggravating reactions following treatment. Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients. As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384).

XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2. The therapy offers three beneficial effects: the ability to neutralize the virus, reduce inflammatory responses, and the absence of aggravating reactions following treatment. Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients. As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384).

No indication information available.

No associated conditions information available.